Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, comments on unmet needs in patients with relapsed/refractory (R/R) AL amyloidosis. Dr Khwaja explains that there are few clinical trials in this setting, and patients have limited treatment options. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.